Therapeutic attribute | Caregivers (N = 137) | Neurologists (N = 161) | ||
---|---|---|---|---|
aMean (SE) | SD (SE) | aMean (SE) | SD (SE) | |
Clinical effects (average): 1-year increment | 0.47 (0.08) | 0.65 (0.01) | 0.82 (0.08) | 0.70 (0.01) |
Clinical effects (variation): wide vs. narrow | 0.12 (0.08) | 0.70 (0.01) | 0.14 (0.07) | 0.75 (0.01) |
Biomarker response (amyloid clearance): 10% increment | 0.20 (0.04) | 0.28 (< 0.01) | 0.26 (0.03) | 0.24 (< 0.01) |
Adverse events (symptomatic ARIA-E): 5% increment | − 0.26 (0.03) | 0.25 (< 0.01) | − 0.52 (0.04) | 0.41 (0.01) |
Treatment duration: 1-year increment | − 0.02 (0.01) | 0.13 (< 0.01) | − 0.13 (0.01) | 0.15 (< 0.01) |
Treatment titration (at initiation): yes vs. no | − 0.19 (0.04) | 0.57 (< 0.01) | − 0.07 (0.02) | 0.35 (< 0.01) |
Treatment administration: IV every 4 vs. 2 weeks | 0.20 (0.09) | 0.83 (0.01) | 1.00 (0.12) | 1.16 (0.02) |
Treatment administration: SC vs. IV every 2 weeks | 0.07 (0.05) | 0.72 (0.01) | 0.42 (0.10) | 1.10 (0.01) |